Contents

  • Current Studies
    1. DOVE — Drager Oscillatory Ventilation Evaluation
    2. Sildenafil for PPHN
    3. HIP — Hernia in Premies
    4. Furosemide — Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia
    5. Remodulin — Intravenous Remodulin (Treprostinil) as Add-On Therapy for the Treatment of PPHN
    6. PaTTerN Registry — Use of iNO in infants
    7. Telemedicine Intubation Study
  • Closed to new enrollment
    1. PENUT Trial — Preterm Epo Neuroprotection
    2. SCAMP — Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP)
    3. IBT — A Trial of Lactobacillus reuteri (A Probiotic) in Preterm Infants
    4. AEROSURF — Aerosolized Surfactant for Treatment of RDS
  • Pending Studies
    1. Cannabadiol for HIE
    2. Mecasermin rinfabate — SHP607 (mecasermin rinfabate) for prevention of BPD
    3. DINE — Developmental Impact of NICU Exposures
    4. Urinary Biomarkers and NIRS in HIE
    5. Direct Peritoneal Resuscitation in Gastroschisis

Current Research Studies

DOVE — Drager Oscillatory Ventilation Evaluation

Sponsor: Drager Inc.

Location: UAMS and ACH

Inclusion Criteria:

  • Gestational Age at birth: 23 – 30 weeks
  • Birth weight: 400 – 1200 grams
  • Chronologic Age: less than 96 hours
  • 5-minute Apgar > 3
  • Clinician would like HFOV

Exclusion Criteria:

  • Already ventilated ≥ 96 hours
  • Major respiratory or cardiac anomalies
  • Pre-existing air leak
  • Known grade III/IV IVH

Contact any of the following:

  • Dr. Courtney 631-682-0812
  • Denise Pearson: 501-364-1065

Sildenafil for PPHN

Sponsor: Pfizer Labs

Location: ACH

Inclusion Criteria:

  • Gestational Age at birth: 34 weeks or greater
  • Chronologic Age: less than 96 hours
  • Diagnosis of PPHN on iNO

Exclusion Criteria:

  • Life-threatening anomalies
  • Diaphragmatic hernia
  • 5-minute Apgar Score < 5

Contact either:

  • Allen Harrison: 501-364-7192 or 404-734-3777 (text preferred) or pager 405-0829
  • Dr. Courtney: 631-682-0812 (text okay)

HIP — Hernia in Premies

Sponsor: Vanderbilt University

Location: ACH and UAMS (for recruitment)

Inclusion Criteria:

  • Gestational Age at birth: less than 37 weeks
  • The presence of an inguinal hernia

Exclusion Criteria:

  • Major anomalies
  • Simultaneous other surgery planned for hernia repair

Contact any of the following:

  • Dr. Dassinger:501-364-2943
  • Kathy Hummel:501-364-2715

Furosemide — Safety in Premature Infants at Risk of Bronchopulmonary Dysplasia

Sponsor: NIH/NICHD and the Pediatric Trials Network

Location: ACH

Inclusion Criteria:

  • Gestational Age at birth: less than 29 weeks
  • Chronologic age: 7–28 days
  • On nCPAP, NIPPV, NC, or mechanical ventilation

Exclusion Criteria:

  • Previous diuretics
  • Significant PDA
  • Certain abnormal lab at admission

Contact any of the following:

  • Andrea Ross: 501-364-3122
  • Dr. Courtney: 631-682-0812

Remodulin — Intravenous Remodulin (Treprostinil) as Add-On Therapy for the Treatment of PPHN

Sponsor: United Therapeutics

Location: ACH

Inclusion Criteria:

  • Gestational age ≥ 34 weeks and weight ≥ 2 kg
  • Chronologic Age: ≤ 14 days
  • Diagnosis of PPHN and currently requiring ventilator support
  • Two consecutive OIs of 15 or greater separated by at least 30 minutes, after receiving iNo for at least 3 hours

Exclusion Criteria:

  • Significant congenital heart disease (CHD)
  • Uncontrolled coagulopathy and/or untreated thrombocytopenia
  • History of severe (Grade 3 or 4) intracranial hemorrhage

Contact any of the following:

  • Allen Harrison: 501-364-7192 or 404-734-3777 (text preferred) or pager 405-0829
  • Dr. Courtney: 631-682-0812

PaTTerN Registry — Use of iNO in infants

Sponsor: Malenkrodt

Location: ACH and UAMS

  • A multicenter observational registry of premature (27 to 34 weeks) and term or near-term infants (34 to 40 weeks) with pulmonary hypertension who are receiving inhaled nitric oxide by either invasive or non-invasive ventilator support.

Tele-intubation Study

Sponsor: NIH/NIGMS (National Institute for General Medical Sciences)

Location: UAMS

Inclusion Criteria:

  • Pediatric and Med-Peds Residents
  • Willing to participate during NICU rotation

Contact:

  • Dr. Whit Hall, 501-296-1397
  • Jimmy Birdsong, RN, 501-526-7838

Closed to New Enrollment

PENUT Trial — Preterm Epo Neuroprotection

Sponsor: NIH/NINDS

Location: UAMS and ACH

All PENUT patients will be followed through two years corrected age
Follow-up is in progress

SCAMP — Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections (SCAMP)

Sponsor: NIH/NICHD and the Pediatric Trials Network

Location: ACH

Data analysis is in progress

IBT — A Trial of Lactobacillus reuteri (A Probiotic) in Preterm Infants

Sponsor: Infant Bacterial Therapeutics

Location: UAMS and ACH

Data analysis is in progress

AEROSURF — Aerosolized Surfactant for Treatment of RDS

Sponsor: Discovery Labs

Location: UAMS

Data analysis is in progress


Last Updated 2017-09-18 15:30 (Maintained by Dr. Courtney and Dr. Walter)